Meati sale puts a price on stranded fermentation capacity

INTRODUCTION

Plant culture developer Ayana Bio and speciality chemicals manufacturer Zenfold have bought mycelium meat producer Meati’s fermentation hardware for $75,000, according to AgFunderNews. The sale redirects food-biomanufacturing capacity from Colorado to plant cell culture in India.

The package includes 12 fermenters, each holding 25,000 litres, plus the equipment used to prepare cultures before they enter those vessels, AgFunderNews reports. Together, the tanks provide 300,000 litres of capacity. Ayana Bio and Zenfold Sustainable Technologies bought them jointly. Vegconomist reports that the partners want the transferred equipment running during the first half of 2027. The purchase gives Ayana Bio an intermediate production step without requiring it to own a complete factory.

Zenfold already operates four vessels with capacities of 100,000 litres each, according to AgFunderNews. Ayana Bio chief executive Frank Jaksch argues that using the smaller Meati units first will reduce the risk of moving an untested process directly into those larger tanks. The logic is plain. A failed batch becomes more costly as vessel size rises. Yet the transaction also shows how little specialised hardware may fetch after the business built around it runs out of money. Stainless steel keeps its physical value. Its commercial value depends on who can remove, install and use it.

THE DECISION

Ayana Bio and Zenfold will dismantle the equipment rather than resume operations at the Thornton site, according to both reports. Zenfold will install the vessels at its own facilities. The partners intend to create a dedicated pilot operation for Ayana Bio’s plant cell development work. They also plan to reserve capacity for later commercial production, AgFunderNews reports. Other plant cell companies will be able to use the pilot facilities, according to both publications. Neither account gives terms for that outside access.

The deal followed an unsuccessful disposal process. An internet auction was due during spring 2026, according to AgFunderNews. Buyers took some equipment, but the principal fermentation system remained unsold. Jaksch told AgFunderNews that Ayana Bio first learnt of the assets during December. The company could not then find a workable route to acquire them. Ayana Bio revisited the opportunity in July 2026 after discovering that much of the equipment was still available. It then opened talks with Zenfold, a business with which Jaksch said Ayana Bio had worked for more than a year.

COLLAPSE

Meati Foods built the Thornton plant to manufacture meat alternatives from mycelium. Vegconomist describes it as one of the largest American facilities devoted to alternative-protein biomass fermentation. The company’s owner, Emergy Inc., entered an Assignment for the Benefit of Creditors process during spring 2025, according to vegconomist. AgFunderNews gives the more specific date of May 2025 and describes the process as an alternative to bankruptcy. Vegconomist reports that a lender had taken most of the company’s available cash. The resulting shutdown permanently removed 150 jobs, according to the publication.

Meati Holdings later acquired the assets under the leadership of Yasir Abdul, according to both reports. Vegconomist says the purchase closed on October 30 and that the new owner announced plans to revive the product range during 2026. Most of the workers who remained subsequently lost their jobs before the end of the year, both publications report. Vegconomist also says unpaid property and sales taxes led to the company’s eviction from Thornton. Those events left the fermentation system detached from the product and workforce for which Meati had installed it.

VALUATION

Jaksch told AgFunderNews that the tanks and their related seed equipment had been worth several million dollars. That valuation comes from the buyer, not an independent appraisal. Vegconomist concludes that the assets changed hands at a small share of their replacement cost. Jaksch identifies stainless-steel expenditure as a longstanding constraint on plant cell and synthetic biology production. The purchase price supports his case that second-hand equipment can reduce initial capital needs. It does not establish the final cost after dismantling, transport, installation and commissioning.

AYANA BIO

Ayana Bio began in 2021 as a venture created by organism-programming company Ginkgo Bioworks, according to vegconomist. Jaksch previously founded supplement business ChromaDex. He told AgFunderNews that Ayana Bio had deliberately avoided operating its own manufacturing site. His preferred model requires the company’s processes to work in standard machinery available from contract manufacturers. The Meati acquisition modifies that approach without wholly abandoning it. Ayana Bio gains dedicated pilot access through a partner, while Zenfold provides the industrial base.

Ayana Bio’s initial commercial focus is rosmarinic acid derived from sage cells, according to both reports. Its other stated targets include saffron cells for crocins and marigold cells for zeaxanthin and lutein. Jaksch told AgFunderNews that recent moves against the synthetic preservative BHA had produced commercial interest in rosmarinic acid as a natural substitute. That demand claim comes from Ayana Bio. Neither source provides orders, customer names, revenue or production volumes to test it.

ZENFOLD

Zenfold was established in late 2021, according to AgFunderNews. The company has its headquarters in Bengaluru and carries out manufacturing and research in Bengaluru and Hyderabad. It works with fine and speciality chemicals through green chemistry, biological conversion and synthetic biology. Those activities give the transferred machinery a use beyond meat alternatives. They also place Ayana Bio’s pilot work beside much larger production vessels, rather than at a stand-alone site created solely for one product range.

Arun Dubey, a Zenfold Sustainable Technologies director and managing partner at Zenfold Ventures, told AgFunderNews that Meati’s problems arose from property and operating costs rather than defective steel. His distinction matters, but the supplied reports contain no independent assessment of the equipment’s condition. Dubey also presents the combination of American biotechnology knowledge and Indian manufacturing as a cost advantage. That remains company positioning until the relocated tanks operate and produce material that meets customer specifications.

THE PROCESS

Plant cell culture grows selected cells inside controlled vessels instead of raising a complete crop in soil. AgFunderNews explains that developers may begin with plant stem cells. They can also induce ordinary tissue to form a callus, a mass of cells capable of continued growth. Producers then cultivate those cells in a liquid suspension. Temperature, nutrients and other conditions can be adjusted towards the compound sought, rather than towards roots, stems, leaves and seeds.

Supporters claim this method can separate botanical ingredient supply from seasons, weather and growing location, according to AgFunderNews. They also argue that controlled production can limit exposure to pesticides, heavy metals, disease and adulteration. A further claim holds that directing cellular metabolism can yield greater concentrations of selected compounds than conventional cultivation. These are general arguments reported by AgFunderNews, not results demonstrated by the Meati equipment purchase. Neither supplied account provides comparative data on yield, energy use, water demand or unit cost for Ayana Bio’s ingredients.

SCALE

The transferred vessels fill a specific gap between laboratory development and Zenfold’s existing industrial equipment. Jaksch told AgFunderNews that a company should have strong confidence in a process before committing it to a 100,000-litre run or several such runs. A 25,000-litre stage can expose mixing, growth and consistency problems before a larger batch puts more material at risk. The rationale is technical as well as financial. The sources do not disclose whether Meati’s system requires modification for plant cells, which differ from the fungal biomass it previously handled.

The same hardware therefore carries two different stories. Meati installed it to make mycelium food at high volume. Ayana Bio and Zenfold intend to use it for compounds made by cultured plant cells. AgFunderNews calls Meati Foods defunct, while vegconomist reports a stated plan by Meati Holdings to relaunch the products. The accounts can be reconciled by separating the former operating company and factory from the later owner’s announced intentions. Neither source reports that a relaunch has occurred.

UNRESOLVED COSTS

Neither publication gives the expense of removing the tanks from Thornton or shipping them overseas. They also omit installation costs, local permits, validation work and any spending needed to adapt the seed trains. No source identifies the seller in the final transaction or explains how Ayana Bio and Zenfold divided the purchase. The $75,000 figure therefore describes only the acquisition price. It cannot support a full comparison with new equipment or contract manufacturing without the missing costs.

The timetable carries similar limits. Jaksch supplies the operating target reported by both publications, but neither account sets out construction stages or regulatory steps. The reports do not identify customers committed to use the shared pilot facility. They provide no production contracts for the proposed bioactives. The evidence supports a cheap asset purchase and a defined technical purpose. It does not yet support claims about commercial output, manufacturing economics or demand at industrial volume.

CONCLUSION

Neither buyer makes meat alternatives, according to vegconomist. That makes the sale less a verdict on fermentation itself than on whether equipment can find a sound use after its original business fails. The decisive test will be operating performance and total relocation cost, not the strikingly low auction-room price.